Skip to main content

Multiple Sclerosis News (Page 6)

Related terms: MS

FDA Medwatch Alert: Gilenya (fingolimod): Drug Safety Communication - Safety Review of a Reported Death After the First Dose

[UPDATED 05/14/2012] FDA has completed its evaluation of a report of a patient who died after the first dose of multiple sclerosis drug Gilenya (fingolimod). The agency also has evaluated additional ...

Novartis Gains FDA Approval For Gilenya, A Novel First-Line Multiple Sclerosis Treatment Shown To Significantly Reduce Relapses And Delay Disability Progression

Basel, September 22, 2010 - Today, Novartis announced that the US Food and Drug Administration (FDA) approved the oral multiple sclerosis (MS) treatment Gilenya (fingolimod) 0.5 mg daily, a...

FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis

The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated...

US FDA Approves Extavia - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with This Devastating Disease

Basel, August 17, 2009 - The US Food and Drug Administration (FDA) has approved Extavia (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related drug support groups

prednisone, methylprednisolone, Medrol, prednisolone, valacyclovir, dexamethasone, Tecfidera, Ocrevus, Gilenya, dimethyl fumarate, Aubagio